| Cat.No. | Name | Information |
|---|---|---|
| M1721 | AZD4547 | AZD4547 is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
| M25005 | Recifercept | Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia. |
| M24907 | Pegbelfermin | Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH). |
| M24759 | Aprutumab | Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
| M24606 | Vofatamab | Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
| M21498 | Bemarituzumab | Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). |
| M20223 | WAY-625530 | WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor. |
| M20221 | WAY-621856 | WAY-621856 is a FGFR inhibitor. |
| M20193 | WAY-603814 | WAY-603814 is a FGFR1 inhibitor |
| M20183 | WAY-600868 | WAY-600868 is a FGFR3 inhibitor. |
| M20165 | WAY-353890 | WAY-353890 is a inhibitor of protein kinase FGFR1 |
| M20050 | WAY-272449 | WAY-272449 is a FGFR1 inhibitor. |
| M20048 | WAY-272130 | WAY-272130 is a FGFR1 inhibitor. |
| M20039 | WAY-270599 | WAY-270599 is a FGFR1 inhibitor |
| M14894 | Ferulic acid sodium | Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
